A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring HCTZ, hypertension, valsartan, amlodipine
Eligibility Criteria
Inclusion criteria Male or female patients ≥18 years of age Non-diabetic patients must have MSSBP of ≥140 mmHg and/or MSDBP ≥90 mmHg at Visits 1 and 2. Diabetic patients must have MSSBP ≥130 mmHg and/or MSDBP ≥80 mmHg at Visits 1 and 2 Patients treated with monotherapy at a dose considered as adequate by the investigator for a minimum of two months prior to Visit 1 Exclusion criteria Known or suspected contraindications, including history of allergy to ARBs, CCB, thiazides or to drugs with similar chemical structure. MSSBP ≥180 mmHg and/or MSDBP ≥110 mmHg (MSSBP ≥160 mmHg and/or MSDBP ≥100 mmHg for diabetic patients) at any time between Visit 1 and Visit 2. Evidence of a secondary form of hypertension, to include coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma. Known Keith-Wagener grade III or IV hypertensive retinopathy. Other exclusion criteria apply
Sites / Locations
- Novartis Pharmaceuticals